4658

New Target for the Treatment of Abdominal Obesity

Monsonego-Ornan Efrat, HUJI, Faculty of Agricultural, Food and Environmental Quality Sciences, Biochemistry, Food Science and Nutrition

 

Category

Metabolic diseases

Keywords

Abdominal obesity, obesity

Current development stage

Pharmaceutical development: TRL2  Hypothesis Formulated       

Collaboration Opportunity

Sponsored Research with an option to License Research Results

Background

Obesity is the leading cause of death in America, and is associated with an increase in chronic diseases like, cardiovascular diseases, hypertension, and metabolic disease involving the liver as well as type 2 diabetes. A recent study has shown a correlation between an overexpression of a specific protein and abdominal obesity, however no follow up studies were carried out to indicate a treatment.

Our Innovation

The researcher has identified several inhibitory small molecules that specifically target the overexpressed protein responsible for abdominal obesity. A small molecule therapy would inhibit the proteins and reduce or prevent abdominal obesity.

Opportunity

The researcher is looking for sponsored research funding from a partner to:

  • Identify the best small molecule for inhibiting the overexpressed proteins.
  • Conduct an in vitro study to elucidate the influence of the small molecule on signaling pathways responsible for abdominal obesity.
  • Conduct an in vivo study developed in the researcher’s lab to see the influences of the small molecule on the model animal.
  • Conduct an analysis of the carcass of the model animals.

 

 

Contact for more information:

Amichai Baron
VP, Head of Business Development, Agritech & Envir
+972-8-9489263
Contact ME: